The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.
Chirag G. Patel
Employment or Leadership Position - Millennium
Mayank Patel
Employment or Leadership Position - Millennium
Arijit Chakravarty
Employment or Leadership Position - Millennium
Esha A. Gangolli
Employment or Leadership Position - Millennium
Stock Ownership - Novartis; Takeda
Elly Barry
Employment or Leadership Position - Millennium
Eric H. Westin
Employment or Leadership Position - Millennium
Katti Jessen
Employment or Leadership Position - Takeda
Stock Ownership - MLN0128
Shripad D. Chitnis
Employment or Leadership Position - Millennium
Jeffrey R. Infante
No relevant relationships to disclose
Michael S. Gordon
Research Funding - Millennium
Teresa Macarulla
No relevant relationships to disclose
Andres Cervantes-Ruiperez
No relevant relationships to disclose
Shadia Ibrahim Jalal
No relevant relationships to disclose
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium